Squarepoint Ops LLC Morphic Holding, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $619,644 - $808,242	23,723 New	23,723 $808,000
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $410,391 - $637,701	20,571 Added 183.82%	31,762 $917,000
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $384,187 - $695,073	11,191 New	11,191 $641,000
Q4 2021 Feb 14, 2022	SELL	$43.27 - $65.72 $446,330 - $677,901	-10,315 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$53.61 - $67.5 $118,049 - $148,635	2,202 Added 27.14%	10,315 $584,000
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $366,139 - $527,263	8,113 New	8,113 $466,000
Q3 2020 Nov 16, 2020	SELL	$22.51 - $30.11 $198,020 - $264,877	-8,797 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.65 - $29.57 $111,282 - $260,127	8,797 New	8,797 $238,000
Q1 2020 May 15, 2020	SELL	$10.84 - $20.85 $431,475 - $829,913	-39,804 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$13.02 - $19.5 $119,901 - $179,575	9,209 Added 30.1%	39,804 $683,000
Q3 2019 Nov 14, 2019	BUY	$17.46 - $29.05 $534,188 - $888,784	30,595 New	30,595 $554,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.